# Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis

> **NCT00630656** · PHASE2 · COMPLETED · sponsor: **Agennix** · enrollment: 190 (actual)

## Conditions studied

- Severe Sepsis

## Interventions

- **DRUG:** Talactoferrin alfa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00630656
- **Lead sponsor:** Agennix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-08
- **Final completion:** 2010-02
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2011-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00630656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00630656, "Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00630656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*